Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Domvanalimab · AB-154

Monoclonal antibody · Inhibitor of TIGIT · developed by Gilead Sciences

Phase 2 Most advanced trial

GILD Developer

1 Registered trials

What is Domvanalimab?

Domvanalimab is a humanized IgG1 monoclonal antibody that binds TIGIT, an immune inhibitory receptor expressed on tumor-infiltrating T lymphocytes. By blocking TIGIT's interaction with CD112 and CD155, it leaves these ligands free to engage the costimulatory receptor CD226, supporting T-cell and NK cell antitumor responses. It is being studied in gastrointestinal tract malignancies.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: AB-154
Drug type: Monoclonal antibody
Targets: TIGIT
Mechanism: Inhibitor of TIGIT
Pathways: CD226 costimulatory signaling, T-cell activation, NK cell activation
Therapy area: Oncology
Developer: Gilead Sciences (GILD)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: 45X7OU8C4J

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05329766	Phase 2	Gastrointestinal Tract Malignancies	Active not recruiting	GILD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Gastrointestinal Tract Malignancies

Other drugs acting on TIGIT

BMS-986442 Phase 1 Dargistotug Phase 2 Rilvegostomig Phase 3 TAB006 Phase 1 Tiragolumab Phase 1/2

More from Gilead Sciences

Axicabtagene Ciloleucel FDA approved Bictegravir FDA approved Brexucabtagene Autoleucel FDA approved Bulevirtide FDA approved Cobicistat FDA approved Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDA approved Emtricitabine And Tenofovir Alafenamide FDA approved Emtricitabine/Tenofovir Disoproxil FDA approved Lenacapavir FDA approved Remdesivir FDA approved Sacituzumab Govitecan FDA approved Seladelpar FDA approved

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the GILD page.

Follow GILD, the company behind Domvanalimab

See GILD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GILD catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z